Group 1 - The core viewpoint of the article is that Juzhi Biotechnology has disclosed the testing results of its recombinant collagen products, which have raised questions regarding the credibility and transparency of the results [2][3]. - Juzhi Biotechnology commissioned four testing institutions (A, B, C, D) to conduct qualitative and quantitative tests on multiple batches of its products, but did not disclose the names of these institutions [2]. - Testing results from institutions A, B, and C confirmed the presence of recombinant collagen in the product with a content greater than 0.1%, while institution D verified that sodium polyglutamate did not interfere with the detection results [2]. Group 2 - The testing results provided by Juzhi Biotechnology were only partial screenshots and lacked the names, stamps, or signatures of the testing institutions, raising doubts about the validity of the reports [3][4]. - The response from Dazui Doctor Yan Research Institute indicated skepticism towards Juzhi Biotechnology's disclosure, highlighting concerns about the lack of transparency in the testing process [5]. - Following the announcement, Juzhi Biotechnology's stock price fell by 1.8%, closing at 65.45 HKD per share, indicating market skepticism regarding the company's claims [5].